In 2024, there will be another big move in the VC PE industry.
Author |Huo Yun.
* |Investor (ID: touzijias).
In 2024, there will be another big move in the VC PE industry.
Industrial capital has made great efforts.
Investor.com learned that Jiu'an Medical, the A-share "demon king" who made crazy money in the United States just by selling kits, is continuing to increase its VC PE. Their subsidiaries have just pulled Tianjin VC Begonia Venture Capital to jointly set up a team with a scale of 35600 million yuan new**.
This is not the first time that the A-share "demon king" has tested the waters of VC PE. In recent years, Jiu'an Medical, which has made a lot of money, seems to have fallen in love with equity investment, and has successively invested in a number of well-known VC PEs such as Jiuhe Venture Capital, Wuyuefeng Capital, Yaotu Capital, and Lisi Capital as an LP, and has used investment to link out a scientific and technological landscape that runs through artificial intelligence, new energy, new materials, and chip semiconductors.
One. Jiu'an Medical is definitely a listed company entering VC PETemplate.
Speaking of Jiu'an Medical, its growth and rise are closely related to changes in the global environment. In 2020, a sudden "black swan" disrupted people's rhythm, and it was from then on that the once unknown Jiu'an Medical completed its self-transformation.
In 2022,Relying on the high-light operation of selling the kit to the United States, Jiu'an Medical once became famous. The company's total profit in the past ten years is only 9With 400 million yuan, they have achieved the leap of "ugly duckling into white swan" in just one quarter. According to the data of that year, Jiu'an Medical's net profit in the first quarter of 2022 is expected to reach 14 billion yuan to 16 billion yuan, a year-on-year increase of more than 367 times.
There is **analysis,".If pressedCalculated in days, it is equivalent to Jiu'an Medical's daily net profit of more than 15100 million yuan, 99% of the hangingof companies. The reason why Jiu'an Medical was able to do business in the United States was thanks to the foresight of the founder Liu Yi. In 2010, he said that smart consumer electronics such as iPhone and iPad will bring a wave of growth opportunities for blood pressure monitors. "Seize the opportunity in advance.
So Liu Yi decided to board the express train of smart consumer electronics, and quickly bought the English trademark in the United States and established a subsidiary. Jiu'an Medical's "going to sea" behavior has attracted the attention of domestic brokers, and in the same year, they landed on A-shares as the "first share of blood pressure monitor".
After Jiu'an Medical went public, Liu Yi was not happy. The company's profitability is difficult and the performance is tepid, even so, he insists on polishing the productsLiu Yi believes that as long as you prepare your homework, you will take off when the opportunity comes. In 2020, the United States has become the hardest hit area of the global "black swan", Liu Yi feels that the time is ripe, Jiu'an Medical will cut into the antigen test as quickly as possible, and the kit will sell well in the United States.
In fact, Jiu'an medical kits can sell well, in addition to Liu Yi's foresight, there is also an advantage that it is cheap and easy to use. It is understood that the price of the kit launched by Jiu'an Medical is about 6$99, far lower than the price of other products in the United States, and in terms of kit practicability, Jiu'an medical kit can be collected by individuals, and the results can be obtained in 15 minutes, which improves the convenience of use.
With the "going to sea" of antigen testing, Jiu'an Medical has become a mess in China and the United States.
Two. This fire quickly burned to the **.
From 2021 to 2022, Jiu'an Medical opened its peak moment in A-shares, of which its stock price soared all the way in half a year, soaring 15 times, and was called the "demon king" of A-shares by shareholders. It is worth mentioning that at the end of 2021, Jiu'an Medical's cash and cash equivalents balance was only 5400 million yuan, but by the end of 2022, this figure has reached 555.9 billion yuan. In that year, Jiu'an Medical created a surge in revenue and net profit, with a revenue of 2631.5 billion yuan, net profit attributable to the parent company of 160300 million yuan.
Jiu'an Medical, who became rich overnight, is also the object of the first report, but Liu Yi's head is very sober.
* Jiu'an Medical, which has experienced the fire, has not let go of itself. Liu Yi, who is well aware of the "environment creates a sharp increase in the company's performance", has done a big thing with fire and cash flow and embraced the VC PE industry. "The money earned in the secondary market is spent in the primary market. ”
Also in 2022, Jiu'an Medical invested in 5 VC PEs with cash in one go, with a total investment of 3400 million yuan. These five institutions are Jifeng Capital, Yuansheng Venture Capital, Wuyuefeng Capital, Yaotu Capital, and Huixin Investment. Interestingly, although Jiu'an Medical is engaged in medical treatment, the VC PE they funded is an investment veteran of new energy, new materials, and chip semiconductors.
In addition to Jifeng Capital's focus on medical care, several others basically revolve around the direction of hard technology. However, Jiu'an Medical's investment this time is not much, and there may be an element of testing the water. It is estimated that Liu Yi is also trying, to find a new way out for the future of Jiu'an Medical.
"Success in a given environment cannot be replicated". Jiu'an Medical, which was popular in 2022, soon ushered in the coldness of 2023, and with the gradual recovery of the world, the scene of the sharp increase in performance in the past is gone, and Jiu'an Medical's bet on VC PE has not stopped.
In 2023, Jiu'an Medical will invest in 4 VC PEs in one go, namely Lisi Capital, MiraclePlus, Innova Angel**, and Jiuhe Venture Capital, with a total investment of 1500 million yuan. Compared with the last investment, Jiu'an Medical's strategy has changed this time, with less amount, clearer stages and clearer directions. The above four institutions are in the early stage of the VC PE circle stage, and all of them focus on artificial intelligence.
The founder of MiraclePlus is Lu Qi, who is known as the "first person in artificial intelligence in China". Even after the first wave of investment, Jiu'an Medical did not relax its vigilance in terms of investment, they narrowed the second wave of investment, and maintained a sense of awe for equity investment.
Three. This may be Jiu'an Medical's own investment strategy.
Because,Layout the second wavevc/peThat year, Jiu'an Medical used the money in its hands to invest in the secondary market. In 2023, Jiu'an Medical issued an announcement saying, "The company and its subsidiaries intend to use their own funds with a maximum amount of no more than 17 billion yuan or equivalent foreign currency for entrusted financial management." In the report, Jiu'an Medical is already the first holder of Xiaopeng Motors, Li Auto, and Weilai Automobile.
Investment**, Jiu'an Medical was lucky to earn a book return of about 1.5 billion yuan. This is easier to understand, why Jiu'an Medical will reduce the second wave of VC PE investment? "Switching and adjusting positions in the primary and secondary markets" is the investment strategy of Jiu'an Medical.
Entering 2024, Jiu'an Medical announced its 2023 performance forecast. According to the information, the company's net profit attributable to the parent company was 1.1 billion yuan to 1.3 billion yuan, a year-on-year decrease of 9189%-93.14%。Jiu'an Medical said, "The company's performance in the reporting period decreased compared with the same period last year, mainly due to the decline in demand for related products in the U.S. market after normalization." "This performance is basically accepted by the market.
As mentioned earlier, "success cannot be replicated in a given environment".
All medical companies have returned to normal, but not all companies can keep a clear head like Jiu'an Medical. Some companies have shone in the past few years, and now they have disappeared or squandered their money inexplicably, and Jiu'an Medical is undoubtedly worth learning from.
Just recently, Jiu'an Medical completed another VC PE investment, and its subsidiaries joined hands with Tianjin local VC Haitang Venture Capital to jointly set up a scale of 35$600 million new**. A few days earlier, Jiu'an Medical also participated in the investment of the mother**.
It can be seen that Jiu'an Medical has once again adjusted its investment strategy and began to join forces with regional capital to consolidate barriers. It is believed that Jiu'an Medical will not be the first case of industrial capital in 2024, and more industry rookies are already on the way.
February** Dynamic Incentive Program